Valcare Medical
Tel Aviv, Israel· Est.
Innovative transcatheter mitral valve repair platform targeting minimally invasive treatment of mitral regurgitation.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Innovative transcatheter mitral valve repair platform targeting minimally invasive treatment of mitral regurgitation.
CardiovascularStructural Heart Disease
Technology Platform
D‑shaped annuloplasty ring with rapid anchoring that repairs the mitral annulus and serves as a docking station for future transcatheter mitral valve prostheses.
Opportunities
Early adoption of a combined repair‑and‑replacement platform could capture a high‑risk MR patient segment and attract strategic partnerships with larger medtech firms.
Risk Factors
Clinical trial outcomes, regulatory approvals, and competition from established edge‑to‑edge and annuloplasty devices pose significant execution risks.
Competitive Landscape
Valcare competes with Abbott’s MitraClip, Edwards Lifesciences, and emerging transcatheter annuloplasty technologies, differentiating itself through a dual‑function D‑shaped ring that enables future valve replacement.